Mankind Pharma Limited has released the pledge on 28,280 equity shares of Bharat Serums and Vaccines Limited (BSVL). These shares constituted 38.68% of the paid-up equity share capital of BSVL.

The release occurred on August 17, 2026, following the completion of a realignment of security cover for the company's existing Non-Convertible Debentures (NCDs). The move removes the previous encumbrance on the BSVL stake held in favor of the Debenture Trustee on behalf of NCD holders.

Security Realignment Details

The company informed stock exchanges that it had received requisite approvals from NCD holders and BSE Limited on July 13, 2026, and July 21, 2026, respectively. In accordance with the terms of the Debenture Trust Deeds as amended, Mankind Pharma created revised security in favor of Catalyst Trusteeship Limited.

This revised security cover is established over tangible and intangible assets of the company and its subsidiaries. The new security structure replaces the earlier pledge on the BSVL shares.

The revised security cover stands at 1.26 times the amount of outstanding NCDs as on date. Consequently, no shares of BSVL are now under pledge for these NCDs.

Regulatory Compliance

The disclosure was made under Regulation 30 and Regulation 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also complies with the SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021.

Hitesh Kumar Jain, Company Secretary and Compliance Officer, signed the intimation to the exchanges.

Mankind Pharma Limited will participate in three investor conferences in Mumbai on August 13 and 17, 2026, providing analysts and investors with direct access to company management. The engagements, comprising one-on-one and group meetings, are designed to discuss the general business outlook using only information already available in the public domain. This proactive engagement allows stakeholders to gauge management sentiment ahead of upcoming reporting periods.

The disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Hitesh Kumar Jain, Company Secretary & Compliance Officer, signed the intimation on August 10, 2026. The notice was submitted to both BSE Limited and National Stock Exchange of India Limited.

The schedule for the upcoming conferences is as follows:

The company emphasized that no unpublished price sensitive information (UPSI) will be disclosed during these interactions. All discussions will remain within the bounds of publicly available data. This standard compliance measure ensures equal access to information for all market participants while preventing insider trading risks.

The intimation has also been uploaded to the company’s website at www.mankindpharma.com for broader accessibility. While the schedule is subject to change due to exigencies on either side, the confirmed dates provide a clear window for institutional and retail investors to seek clarifications on strategic initiatives.

What the Numbers Show

The decision to participate in multiple high-profile conferences, including the Motilal Oswal 22nd Annual Global Investor Conference, signals management’s intent to maintain active dialogue with the investment community. By scheduling these meetings in quick succession over a four-day period, Mankind Pharma aims to efficiently address investor queries regarding its operational trajectory and market positioning without delaying routine business activities.